Nichol Ochsner | Vice President of Investor Relations |
Christal Mickle | Co-Founder, Chief Product Development Officer and Interim CEO |
LaDuane Clifton | Chief Financial Officer |
Josh Schafer | Chief Commercial Officer and Executive Vice President, Business Development |
Oren Livnat | H.C. Wainwright |
Sumant Kulkarni | Canaccord |
Jonathan Aschoff | ROTH MKM |
Good morning, and welcome to the Zevra Therapeutics Second Quarter 2023 Corporate and Financial Results Conference Call. [Operator Instructions] Please be advised that today's call is being recorded.
I will now turn the call over to Nichol Ochsner, Zevra Therapeutics Vice President, Investor Relations and Corporate Communications. Thank you.
You may begin.